Resilience, a recently launched manufacturing and technology company for biologics and advanced therapies, will receive a CAD 199.2-million ($164-million) investment from the Canadian government, to modernize and expand the biomanufacturing site of its Mississauga, Ontario, Canada-based subsidiary, Resilience Biotechnologies Inc. (RBI).

This project will help increase manufacturing capacity for vaccines and therapeutics, including novel technologies such as mRNA that are now being used to fight COVID-19.

Last month (April 2021), Resilience acquired the 136,000-square-foot RBI biomanufacturing plant in Mississauga that currently provides process and analytical development, scale-up, drug- substance, drug-product, and fill-finish manufacturing for a variety of medicines.

Additionally in April (April 2021), Resilience acquired a facility in Boston, Massachusetts from Sanofi, and separately acquired Ology Bioservices, an Alachua, Florida-based biologics CDMO.

Resilience was launched in November 2020 with initial capital of $800 million with a specific focus on manufacturing innovation, including for new modalities. Its executive leadership includes Patrick Yang, Ph.D., Vice Chairman, Resilience, and former Executive Vice President and Global Head of Technical/Product Operations, Roche/Genentech, and Rahul Singhvi, Sc.D., CEO, and Director, and former Chief Operating Officer of Takeda’s Vaccine business, where he was responsible for worldwide vaccine CMC and manufacturing operations. Before Takeda, Dr. Singhvi was President and CEO of Novavax, a Gaithersburg, Maryland-based vaccine company, from 2005 to 2011.

Source: Resilience